Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective StudyScientific Letter Published on 2023-11-012024-09-05 Journal: Journal of Heredity [Category] update2024, [키워드] B-cell malignancies COVID-19 pre-exposure Prophylaxis Tixagevimab-cilgavimab [DOI] 10.4084/MJHID.2023.061 PMC 바로가기 [Article Type] Scientific Letter
The L-DBF vaccine cross protects mice against different Shigella serotypes after prior exposure to the pathogenL-DBF 백신은 병원체에 대한 이전 노출 후 다양한 시겔라 혈청형에 대해 쥐를 교차 보호합니다.Article Published on 2023-10-032024-07-28 Journal: Microbiology Spectrum [Category] 세균성이질, [키워드] IFN-γ IL-17 IL-6 IpaB IpaD pre-exposure Shigellosis Vaccine [DOI] 10.1128/spectrum.00062-23 PMC 바로가기
Re: ‘clinical characteristics of ambulatory and hospitalised patients with monkeypox virus infection’ by Mailhe et alComment Published on 2023-02-012023-06-09 Journal: Clinical microbiology and infection : the official [Category] Fulltext, 원숭이두창, [키워드] Monkeypox MSM pre-exposure smallpox vaccination [DOI] 10.1016/j.cmi.2022.10.010 PMC 바로가기 [Article Type] Comment
Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed PigsOriginal Research Published on 2021-11-032023-06-08 Journal: Frontiers in Immunology [Category] Fulltext, 신종인플루엔자, [키워드] aerosol influenza A intramuscular intranasal pdmH1N1 pig pre-exposure Vaccine [DOI] 10.3389/fimmu.2021.763912 PMC 바로가기 [Article Type] Original Research
Effect of Pre-exposure Use of Amantadine on COVID-19 Infection: A Hospital-Based Cohort Study in Patients With Parkinson’s Disease or Multiple SclerosisNeurology Published on 2021-10-072022-11-01 Journal: Frontiers in Neurology [Category] COVID-19, [키워드] 95% CI acute respiratory syndrome adjusted age amantadine conducted confounders Contact control group coronavirus COVID case COVID cases COVID-19 COVID-19 disease COVID-19 infection diagnose disease Effect greater history hospital Increased Infection inhibit lipid bilayer logistic regression model Multiple multiple sclerosis Parkinson's Disease Patient patients pre-exposure prevention of COVID-19 questionnaire random randomized clinical trial reduced risk Registered retrospective cohort study risk risk factor SARS-CoV-2 sclerosis selected significantly supported the patient variables [DOI] 10.3389/fneur.2021.704186 PMC 바로가기 [Article Type] Neurology
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusionsOpen Letter Published on 2021-09-212022-10-28 Journal: Wellcome Open Research [Category] COVID-19, [키워드] adverse event Analysis controls coronavirus COVID-19 death drug drug discontinuation evaluated Evidence Guidance guideline Hospital admission Hospital admissions Hydroxychloroquine Interpretation Mortality not reduce ongoing trial pre-exposure Prevent prevention of COVID-19 Prophylaxis randomised controlled trial RCT RCTs Research SARS-CoV-2 significantly increased statistical analysis statistically significant difference the disease Tolerability Treatment WHO WHO guideline World Health Organization [DOI] 10.12688/wellcomeopenres.16741.2 PMC 바로가기 [Article Type] Open Letter
Potential Prophylactic Treatments for COVID-19Covid-19에 대한 잠재적 예방 치료Review Published on 2021-07-022022-09-10 Journal: Viruses [Category] SARS, 치료제, [키워드] accumulate addition Antiviral antivirals approved Asymptomatic Candidates causative agent clinical trial clinically concern conducted coronavirus disease Coronavirus disease 2019 COVID-19 death disease drug Effectiveness Efficacy Emergency Emergency use expected Health Organization Human indication Inflammatory information majority medications Mild molecular morbidity and mortality multi-organ failure outbreak pandemic post-exposure Potential pre-exposure Prophylactic Prophylaxis provided Public public health emergency Repurposed drugs Research respiratory Respiratory droplets Respiratory failure Safe safety profile SARS-CoV-2 severity Spread the SARS-CoV-2 Treatment Vaccine virus World Health Organization [DOI] 10.3390/v13071292 PMC 바로가기 [Article Type] Review
Health Care Workers’ Reasons for Choosing Between Two Different COVID-19 Prophylaxis Trials in an Acute Pandemic Context: Single-Center Questionnaire Study급성 전염병 상황에서 의료 종사자가 두 가지 다른 COVID-19 예방 실험 중에서 선택하는 이유: 단일 센터 설문 조사 연구Original Paper Published on 2021-02-252022-09-10 Journal: Journal of Medical Internet Research [Category] MERS, 임상, [키워드] Adverse reaction Adverse reactions all subject all subjects asked benefit chose clinical trial clinical trials combination therapy contribute COVID-19 Efficacy emtricitabine evaluate expected followed by Health health benefits Health care Health care worker health care workers Hydroxychloroquine independent initial screening initiated majority melatonin motivation Nurse Nurses objective offered pandemic personnel physician Placebo pre-exposure professional practice Prophylaxis prophylaxis strategy Randomized reason respond Result Safety SARS-CoV-2 SARS-COV-2 infection screened selected significant difference significant differences tenofovir tenofovir disoproxil tested Treatment Trial trials Volunteer volunteers volunteers, web-based survey workplace safety [DOI] 10.2196/23441 PMC 바로가기 [Article Type] Original Paper
Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trialLetter Published on 2020-07-292022-10-29 Journal: Trials [Category] COVID-19, SARS, [키워드] 1:1 acute respiratory syndrome Adults adverse event antiretroviral Antiviral Arm Barcelona blinded Blood Breastfeeding Chloroquine condition confirmed case confirmed COVID-19 case Contact Control control group Controlled clinical trial coronavirus coronavirus disease Corticosteroid COVID-19 declining defined develop disease dissemination double-blind double-blinded Efficacy element eligibility Epidemic equipment evaluate Follow-up group healthcare worker Healthcare workers high risk hospital Hydroxychloroquine hydroxychloroquine treatment identify incidence Infection Intervention intervention group investigator marker multicentre National number Nurse objective Occurrence Older outcome participant Participants PCR physical Placebo placebo tablet polymerase chain positive PCR PPE pre-exposure predict predictor Pregnancy primary endpoint Prophylaxis protocol random randomisation randomised randomised controlled trial Randomized Randomized controlled trial Rapid diagnostic test RDT reached receive recruited reducing Registered Repository Research risk Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR Secondary endpoints Seroconversion serological serology serum sample Spain Spanish Standard of care status Study protocol Symptom Tablet the placebo group the SARS-CoV-2 Treatment Trial website with COVID-19 [DOI] 10.1186/s13063-020-04621-7 PMC 바로가기 [Article Type] Letter